Apellis Stock Analysis

APLS
 Stock
  

USD 68.30  2.89  4.42%   

The latest price spike of Apellis Pharmaceuticals could raise concerns from retail investors as the firm is trading at a share price of 68.30 on 2,101,584 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.99. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Apellis Pharmaceuticals partners.
Please continue to Trending Equities.
  
The Apellis Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Apellis Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Apellis Stock analysis module also helps to analyze the Apellis Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Apellis Stock Analysis Notes

About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.7. Apellis Pharmaceuticals had not issued any dividends in recent years. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. For more info on Apellis Pharmaceuticals please contact Cedric Francois at 617 977 5700 or go to https://www.apellis.com.

Apellis Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Apellis Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Apellis Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Apellis Pharmaceuticals appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 80.94 M. Net Loss for the year was (701.63 M) with loss before overhead, payroll, taxes, and interest of (253.92 M).
Apellis Pharmaceuticals currently holds about 965.3 M in cash with (521.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.06.
Over 91.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Apellis Pharmaceuticals exotic insider transaction detected

Apellis Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Apellis Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apellis Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report27th of April 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Apellis Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Apellis Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Apellis Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Apellis Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
24th of August 2022
Other Events
View
2nd of August 2022
Financial Statements and Exhibits. Other Events. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
27th of July 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
19th of July 2022
Other Events
View
2nd of June 2022
Submission of Matters to a Vote of Security Holders
View
24th of March 2022
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
View
16th of March 2022
Other Events
View
14th of February 2022
Unclassified Corporate Event
View

Apellis Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Apellis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Apellis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wellington Management Group LlpCommon Shares11.5 M522 M
Avoro Capital Advisors LlcCommon Shares9.8 M443.4 M
Vanguard Group IncCommon Shares8.7 M394.6 M
Price T Rowe Associates IncCommon Shares8.7 M392.5 M
Blackrock IncCommon Shares6.8 M307.4 M
Ecor1 Capital LlcCommon Shares5.2 M234.4 M
State Street CorpCommon Shares3.5 M158.1 M
Deerfield Management Company Lp Series CDebt51.9 M76.5 M
Note, although Apellis Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Apellis Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 6.37 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Apellis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Apellis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (34.55) % which means that it has lost $34.55 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (273.06) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals management efficiency ratios could be used to measure how well apellis pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 3rd of October, Apellis Pharmaceuticals shows the risk adjusted performance of 0.2089, and Mean Deviation of 2.96. Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Apellis Pharmaceuticals, which can be compared to its rivals. Please confirm Apellis Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 68.3 per share. Given that Apellis Pharmaceuticals has jensen alpha of 0.8604, we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Apellis Pharmaceuticals Price Movement Analysis

Study
Start Value
Offset on Reverse
AF Init Long
AF Long
AF Max Long
AF Init Short
AF Short
AF Max Short
Execute Study
The output start index for this execution was one with a total number of output elements of sixty. The Extended Parabolic SAR indicator is used to determine the direction of Apellis Pharmaceuticals's momentum and the point in time when it has higher than normal probability of directional change. It has more input parameters than standard Parabolic SAR indicator.
.

Apellis Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apellis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apellis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apellis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alec Machiels over two weeks ago via Macroaxis 
Exercise or conversion by Alec Machiels of 1250 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Pascal Deschatelets over two weeks ago via Macroaxis 
Exercise or conversion by Pascal Deschatelets of 18500 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Dunlop A Sinclair over three weeks ago via Macroaxis 
Apellis Pharmaceuticals exotic insider transaction detected
Adam Townsend over three weeks ago via Macroaxis 
Exercise or conversion by Adam Townsend of 5000 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Federico Grossi over a month ago via Macroaxis 
Sale by Federico Grossi of 2500 shares of Apellis Pharmaceuticals
Chopas James George over a month ago via Macroaxis 
Payment of 558 shares by Chopas James George of Apellis Pharmaceuticals subject to Rule 16b-3
Dunlop A Sinclair over a month ago via Macroaxis 
Exercise or conversion by Dunlop A Sinclair of 4306 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Delong Mark Jeffrey over a month ago via Macroaxis 
Exercise or conversion by Delong Mark Jeffrey of 5000 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Dunlop A Sinclair over a month ago via Macroaxis 
Exercise or conversion by Dunlop A Sinclair of 25394 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Adam Townsend over a month ago via Macroaxis 
Exercise or conversion by Adam Townsend of 12500 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Delong Mark Jeffrey over a month ago via Macroaxis 
Exercise or conversion by Delong Mark Jeffrey of 5000 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Delong Mark Jeffrey over a month ago via Macroaxis 
Exercise or conversion by Delong Mark Jeffrey of 5000 shares of Apellis Pharmaceuticals subject to Rule 16b-3

Apellis Pharmaceuticals Technical and Predictive Indicators

Apellis Pharmaceuticals Forecast Models

Apellis Pharmaceuticals time-series forecasting models is one of many Apellis Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Apellis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Apellis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Apellis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Apellis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Apellis Pharmaceuticals. By using and applying Apellis Stock analysis, traders can create a robust methodology for identifying Apellis entry and exit points for their positions.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people.

Current Apellis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Apellis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Apellis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
69.14Buy14Odds
Apellis Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Apellis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Apellis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Apellis Pharmaceuticals, talking to its executives and customers, or listening to Apellis conference calls.
Apellis Analyst Advice Details

Apellis Stock Analysis Indicators

Apellis Pharmaceuticals stock analysis indicators help investors evaluate how Apellis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Apellis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Apellis Pharmaceuticals stock analysis, traders can identify Apellis Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio8.35
Fifty Two Week Low30.17
Shares Short Prior Month9.15M
Average Daily Volume Last 10 Day1.14M
Average Daily Volume In Three Month1.31M
Shares Percent Shares Out8.79%
Short Percent Of Float12.05%
Forward Price Earnings-14.87
Float Shares80.7M
Fifty Two Week High70.00
Enterprise Value To Ebitda-9.72
Fifty Day Average61.67
Two Hundred Day Average49.34
Enterprise Value To Revenue64.74
Please continue to Trending Equities. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for analysis

When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.